Delivery of radioimmunotherapy for solid tumors

Shailendra K. Gautam, Vipin Dalal, Maneesh Jain, Surinder K. Batra

Research output: Chapter in Book/Report/Conference proceedingChapter


The clinical success of radioimmunotherapy (RIT) in hematological malignancies could not be recapitulated to treat solid tumors. The delivery of macromolecule-based RIT agents in solid tumors is challenging due to a complex tumor microenvironment that includes disrupted vascular transport and stroma induced physical and biochemical impediments. The inter- and intratumoral heterogeneities within and across the solid malignancies result in disproportionate delivery of radioimmunoconjugates (RICs). As the tumor-specific monoclonal antibodies and therapeutic radionuclides are two core components of RIT, several efforts have been directed to optimize the size, stability, and delivery of RICs to develop clinically relevant alternatives of conventional radiotherapy. Nevertheless, recent trends are more focused on combining RIT with chemotherapies, immunotherapies, antistromal therapies, and antivascular therapies to enhance tumor-specific delivery and therapeutic efficacy. In this chapter, we discuss the major challenges and recent efforts to improve the effectiveness of RIT in solid tumors.

Original languageEnglish (US)
Title of host publicationSystemic Drug Delivery Strategies
Subtitle of host publicationVolume 2 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy
Number of pages25
ISBN (Electronic)9780323857819
StatePublished - Jan 1 2021


  • Combination therapy
  • Drug delivery
  • Monoclonal antibodies
  • Radioimmunotherapy
  • Solid tumors
  • Stroma
  • Tumor microenvironment
  • Vascular transport

ASJC Scopus subject areas

  • Economics, Econometrics and Finance(all)
  • Business, Management and Accounting(all)


Dive into the research topics of 'Delivery of radioimmunotherapy for solid tumors'. Together they form a unique fingerprint.

Cite this